Skip to main content
Premium Trial:

Request an Annual Quote

Spain's Integromics Opens US HQ in Philly Science Center

NEW YORK (GenomeWeb News) – Integromics, a life sciences software company based in Granada, Spain, has opened its US headquarters at the University City Science Center in Philadelphia, the company said yesterday.
The company said it has expanded into the US in order to be closer to current and prospective customers and business partners.
Integromics said the new office will include sales and marketing, scientific, and customer support staff.
Howard Bilofsky, a senior fellow in the School of Engineering and Applied Science at the University of Pennsylvania and a former senior executive at GlaxoSmithKline, will serve as vice president of the company and lead US operations.
The company offers data management, integration, and analysis solutions for public and private life sciences customers.
Integromics said that the University Science Center offers a “Soft-Landing Program” that assists international companies seeking to expand into the US market by providing space, funding, and "domestic market expertise."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.